Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GPX4 | P36969 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359365 | 0.84 | MAPT (0.43) | SYKNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL12505377 | 0.80 | SYK (0.48) | SYKNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL358289 | 0.79 | SYK (0.46) | SYKRAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL358514 | 0.76 | SYK (0.55) | SYKNPC1RAB9AKMT2AKDM4E | |
| SCHEMBL19265894 | 0.76 | IRAK4 (0.52) | SYKNPC1RAB9AKMT2AKDM4E | |
| SCHEMBL31182014 | 0.68 | PIN1 (0.68) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL359660 | 0.67 | SYK (0.65) | SYKIRAK4IRAK1 | |
| SCHEMBL19265812 | 0.66 | PTK2 (0.50) | SYKSMN1; SMN2IRAK4IRAK1ALDH1A1 | |
| SCHEMBL19677062 | 0.66 | PTK2 (0.50) | SYKKMT2AKDM4ESMN1; SMN2IRAK4 | |
| SCHEMBL14977553 | 0.66 | SYK (0.66) | SYKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | SYK 634/4885NPC1 2973/4885RAB9A 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.